TY - JOUR
T1 - Networking for ovarian rare tumors
T2 - A significant breakthrough improving disease management
AU - Chiannilkulchai, N.
AU - Pautier, P.
AU - Genestie, C.
AU - Bats, A. S.
AU - Vacher-Lavenu, M. C.
AU - Devouassoux-Shisheboran, M.
AU - Treilleux, I.
AU - Floquet, A.
AU - Croce, S.
AU - Ferron, G.
AU - Mery, E.
AU - Pomel, C.
AU - Penault-Llorca, F.
AU - Lefeuvre-Plesse, C.
AU - Henno, S.
AU - Leblanc, E.
AU - Lemaire, A. S.
AU - Averous, G.
AU - Kurtz, J. E.
AU - Ray-Coquard, I.
N1 - Publisher Copyright:
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Rare ovarian tumors represent >20% of all ovarian cancers. Given the rarity of these tumors, natural history, prognostic factors are not clearly identified. The extreme variability of patients (age, histological subtypes, stage) induces multiple and complex therapeutic strategies. Methods: Since 2011, a national network with a dedicated system for referral, up to 22 regional and three national reference centers (RC) has been supported by the French National Cancer Institute (INCa). The network aims to prospectively monitor the management of rare ovarian tumors and provide an equal access to medical expertise and innovative treatments to all French patients through a dedicated website, www.ovaire-rare.org. Results: Over a 5-year activity, 4612 patients have been included. Patients' inclusions increased from 553 in 2011 to 1202 in 2015. Expert pathology review and patients' files discussion in dedicated multidisciplinary tumor boards increased from 166 cases in 2011 (25%) to 538 (45%) in 2015. Pathology review consistently modified the medical strategy in 5-9% every year. The rate of patients' files discussed in RC similarly increased from 294 (53%) to 789 (66%). An increasing number (357 in 5 years) of gynecologic (non-ovarian) rare tumors were also registered by physicians seeking for pathological or medical advice from expert tumor boards. Conclusion: Such a nation-wide organization for rare gynecological tumors has invaluable benefits, not only for patients, but also for epidemiological, clinical and biological research.
AB - Rare ovarian tumors represent >20% of all ovarian cancers. Given the rarity of these tumors, natural history, prognostic factors are not clearly identified. The extreme variability of patients (age, histological subtypes, stage) induces multiple and complex therapeutic strategies. Methods: Since 2011, a national network with a dedicated system for referral, up to 22 regional and three national reference centers (RC) has been supported by the French National Cancer Institute (INCa). The network aims to prospectively monitor the management of rare ovarian tumors and provide an equal access to medical expertise and innovative treatments to all French patients through a dedicated website, www.ovaire-rare.org. Results: Over a 5-year activity, 4612 patients have been included. Patients' inclusions increased from 553 in 2011 to 1202 in 2015. Expert pathology review and patients' files discussion in dedicated multidisciplinary tumor boards increased from 166 cases in 2011 (25%) to 538 (45%) in 2015. Pathology review consistently modified the medical strategy in 5-9% every year. The rate of patients' files discussed in RC similarly increased from 294 (53%) to 789 (66%). An increasing number (357 in 5 years) of gynecologic (non-ovarian) rare tumors were also registered by physicians seeking for pathological or medical advice from expert tumor boards. Conclusion: Such a nation-wide organization for rare gynecological tumors has invaluable benefits, not only for patients, but also for epidemiological, clinical and biological research.
KW - Clinical practice guidelines
KW - Gynecological rare cancers
KW - National network
KW - Ovarian rare tumors
KW - Reference centers
UR - http://www.scopus.com/inward/record.url?scp=85021101852&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdx099
DO - 10.1093/annonc/mdx099
M3 - Article
C2 - 28398524
AN - SCOPUS:85021101852
SN - 0923-7534
VL - 28
SP - 1274
EP - 1279
JO - Annals of Oncology
JF - Annals of Oncology
IS - 6
ER -